Benitec Limited (ASX:BLT) (PINK:BNIKF), a world leader in expressed gene silencing for human therapeutics, today announces the formation of the Benitec Chief Investigators' Group, bringing together the Company's scientific founders with its collaborative partners.
Benitec Limited (ASX:BLT) (PINK:BNIKF) announce that the United States Patent and Trademark Office has today indicated that it is issuing the Re-examination Certificate, the formal final step in the USPTO's confirmation of patentability of claims in the key '099 Graham Patent [US Patent No. 6,573,099] "Genetic Constructs for Delaying or Repressing the Expression of a Target Gene", the wide-ranging platform technology patent covering the use of expressed RNA Interference in human therapeutic applications.
Australian Market Report of February 14, 2011 includes: Black Fire Minerals Limited (ASX:BFE) is to acquire 100% of the advanced Pilot Mountain Tungsten-Copper Project in Nevada, USA; Virax Holdings Limited (ASX:VHL) is to develop a novel skin cancer product; Southern Cross Goldfields Limited (ASX:SXG) discovered near-surface high-grade gold deposits in Western Australia; Prosperity Resources Limited (ASX:PSP) commenced gold drilling in Indonesia.
Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today reported that it had issued an additional 24,702,056 ordinary shares to global biopharmaceutical company Cephalon Inc. (NASDAQ:CEPH), and received an additional cash injection of A$139 million. Mesoblast's total cash reserves are now approximately A$280 million.
Universal Biosensors, Inc. (ASX:UBI) today announced that LifeScan's new product, OneTouch Verio (R) has been made available for sale in France. The OneTouch Verio (R) incorporates technology developed by Universal Biosensors and addresses the rapidly growing Self Monitoring Blood Glucose market.
The strategic alliance between regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), and global biopharmaceutical company, Cephalon Inc. (NASDAQ:CEPH), was highlighted at the 29th annual JP Morgan Healthcare Conference in San Francisco yesterday.
Cephalon, Inc. (NASDAQ:CEPH) and Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today announced positive interim results from Mesoblast's ongoing multi-center Phase 2 trial of its "off-the-shelf" proprietary adult stem cell product Revascor (TM) for patients with congestive heart failure.
